Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SIGA Technologies Inc
SIGA | US
5.26
USD-0.21
-3.84%
SIGA | US
About SIGA Technologies Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
13/03/2026
Close
5.26
Open
5.46
High
5.52
Low
5.12
SIGA Technologies Inc. a commercial-stage pharmaceutical company focuses on the health security related markets in the United States. Its lead product is TPOXX an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York New York.
View LessSIGA | US
Risk
38.0
Sharpe
-0.16
Luna's Score
45/100
Recommendation
Sell
Luna says (SIGA | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
45.9%1 month
38.0%3 months
34.1%6 months
45.9%Returns
Fundamental Ratios
PE
5.91
Fwd. PE
5.69
Price to book
3.01
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
3.86
Ent. to rev.
2.30
PEG
-
Other Fundamentals
EBITDA
103.28M
MarketCap
375.40M
MarketCap(USD)
375.40M
Div. yield
-
Op. margin
4.95
Erngs. growth
272.10
Rev. growth
271.00
Ret. on equity
57.59
Short ratio
6.82
Short perc.
10.87
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.53
Range1M
1.91
Range3M
2.00
Volumes: Market Activity
Rel. volume
1.30
Price X volume
4.12M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 3.86 | - | Expensive |
| Ent. to Revenue | 2.30 | - | Cheaper |
| PE Ratio | 5.91 | 41.03 | Cheaper |
| Price to Book | 3.01 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 34.06 | - | Lower Risk |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 375.40M | - | Emerging |
